Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 19/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 19/20 | 0.72 |
| ▸ | CHRM5 | P08912 | 19/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 19/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 19/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398778 | 0.69 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7400439 | 0.67 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7399973 | 0.67 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8154245 | 0.66 | NPC1 (1.00) | NPC1RAB9A | |
| SCHEMBL7398654 | 0.65 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7399616 | 0.65 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4692117 | 0.65 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1059425 | 0.65 | CHRM2 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7396208 | 0.64 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7397953 | 0.64 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015185-A1 | Benzofuran Compounds | BIOVITRUM AB (SE) | 2011-01-20 | — | — | US | disclosed |
| US-7820675-B2 | Benzofuran compounds | BIOVITRUM AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20060287291-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2006-12-21 | — | — | US | disclosed |
| EP-1694663-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | Biovitrum Aktiebolag (SE) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058858-A1 | NOVEL BENZOFURAN DERIVATIVES, WHICH CAN BE USED IN PROPHYLAXIS OR TREATMENT OF 5-HT6 RECEPTOR-RELATED DISORDER | BIOVITRUM AB (SE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287291-A1 | Compounds | HTR6, HTR1B, HTR1A | CHRM2 87/4885CHRM4 152/4885CHRM5 59/4885 |
| US-20110015185-A1 | Benzofuran Compounds | HTR6, HTR1F, HTR1A | CHRM2 317/4885CHRM4 567/4885CHRM5 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.